KRAS G12C针对性共价抑制剂对癌症治疗具有革命性的意义。然而，KRAS G12C抑制剂在临床试验中出现了抗药性是已经被证实的事实。作者们的重点是从临床治疗的角度提供覆盖范围，并强调征服KRAS G12C抑制剂耐药性的策略。作者还为读者提供了他们未来发展的专业视角。通过在临床实践中积累药物抗性机制的快速探索和发展合理的组合剂量方法，提高治疗效果，实现长期的疾病控制是必要的。我们的展示角度为这一突破性研究领域中的药物抗性提供了洞察。

KRAS G12C targeted covalent inhibitors for cancer therapy are revolutionary. However, resistance to KRAS G12C inhibitors in clinical trials is a proven fact.The authors focus on providing coverage and emphasizing the strategy of conquering KRAS G12C inhibitor resistance from the perspective of clinical therapy. The authors also provide the readers with their expert perspectives for future development.It is essential to improve the therapeutic effect and achieve long-term disease control through accumulating rapid exploration of drug resistance mechanisms in preclinical trials and developing rational combination dosing approaches from clinical practice. Our presentation of the perspective provides insights into drug resistance in this groundbreaking area of research.